Fig 3.

Reactivity of serum specimens. (A) At the CDC, the reactivity of serum specimens from patients with B. procyonis (strips A1 to A9) or Toxocara (strips B1 to B10) was tested using rBpRAG1 Western blot strips. Strip A1, sample from a patient diagnosed with baylisascariasis; strip A3, sample from the same patient 3 years postinfection. Patient samples that were positive for Toxocara by EIA (CDC) were tested using the rBpRAG1 strips (strips B1 to B10). The positive and negative controls were an anti-B. procyonis-positive baboon serum (strip B11) and a normal human serum sample (strip B12), respectively. The arrow identifies rBpRAG1. (B) At the NRCP, the rBpRAG1 reactivity of serum specimens from patients with Chagas disease (lanes 1 to 3), trichuriasis (lanes 4 and 5), strongyloidiasis (lanes 6 to 8), toxocariasis (lanes 9 to 11), echinococcosis (lanes 12 to 14), or filariasis (lanes 15 and 16) was tested. Western blot controls included a healthy human serum pool (−) and B. procyonis-infected baboon serum (+). Positive reactions are shown in lane 15. Numbers on the left indicate molecular mass markers (in kDa).